UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria

Iriemenam, NC; Ige, FA; Greby, SM; Mpamugo, A; Abubakar, AG; Dawurung, AB; Esiekpe, MK; ... Audu, R; + view all (2022) Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria. PLOS ONE , 17 (4) , Article e0266184. 10.1371/journal.pone.0266184. Green open access

[thumbnail of journal.pone.0266184.pdf]
Preview
Text
journal.pone.0266184.pdf - Published Version

Download (724kB) | Preview

Abstract

Objective: There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen assays have shown some limitations in Africa. To assess the performance of a multi-antigen assay, we evaluated a commercially available SARS-CoV-2 Multi-Antigen IgG assay for human coronavirus disease 2019 (COVID-19) in Nigeria. / Methods: Validation of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was carried out using well-characterized SARS-CoV-2 reverse transcription polymerase chain reactive positive (97) and pre-COVID-19 pandemic (86) plasma panels. Cross-reactivity was assessed using pre-COVID-19 pandemic plasma specimens (213) from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). / Results: The overall sensitivity of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was 75.3% [95% CI: 65.8%– 82.8%] and specificity was 99.0% [95% CI: 96.8%– 99.7%]. The sensitivity estimate increased to 83.3% [95% CI: 70.4%– 91.3%] for specimens >14 days post-confirmation of diagnosis. However, using the NAIIS pre-pandemic specimens, the false positivity rate was 1.4% (3/213). / Conclusions: Our results showed overall lower sensitivity and a comparable specificity with the manufacturer’s validation. There appears to be less cross-reactivity with NAIIS pre-pandemic COVID-19 specimens using the xMAP SARS-CoV-2 Multi-Antigen IgG assay. In-country SARS-CoV-2 serology assay validation can help guide the best choice of assays in Africa.

Type: Article
Title: Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1371/journal.pone.0266184
Publisher version: https://doi.org/10.1371/journal.pone.0266184
Language: English
Additional information: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
Keywords: SARS CoV 2, Reverse transcriptase-polymerase chain reaction, Serology, COVID 19, Pandemics, Virus testing, Cross reactivity, Antibodies
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery.ucl.ac.uk/id/eprint/10149269
Downloads since deposit
21Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item